ASXL1 and myelodysplastic syndrome: Although inhibitors targeting TET2 mutations have not yet been developed, patients harboring TET2 mutations but lacking ASXL1 mutations showed high response rates to HMAs, indicating that they can be used as a predictor for treatment response in MDS patients (107).